Oxford Biomedica is aiming to improve the yield and quality of next-gen gene therapy vectors using the cloud and machine learning via a new R&D collaboration with Microsoft.
The collaboration will combine the expertise of Oxford Biomedica researchers and the team within the Station B initiative at Microsoft to explore new ways to increase the yield and improve the purity of Oxford Biomedica’s lentiviral vectors, while further reducing the cost.
Oxford Biomedica will contribute large data sets for analysis via the Microsoft Azure intelligent cloud platform.
Microsoft, in collaboration with Oxford Biomedica scientists, will utilise its cloud computing and machine learning capabilities to develop in silico models and novel algorithms to help advance the next generation of cell and gene delivery technology.
The collaboration will run for an initial two-year period and may be extended by either party.
Jason Slingsby, Chief Business Officer of Oxford Biomedica, said: “Our goal is to enable faster, cheaper and more reliable manufacture of high quality next-generation cell and gene therapies to allow more patients to benefit.”
Andrew Phillips, Head of Biological Computation at Microsoft, added: “Programming biology has the potential to solve some of the world’s toughest problems in medicine, and to lay the foundations for a future bioeconomy based on sustainable technology.”